Our Lab
Our Scientific Approach:
Our goal is to develop novel therapies for immune-related diseases by engineering novel solutions. To accomplish this, we first utilize high-dimensional approaches on human disease to identify targetable disease-promoting molecular defects. Second, we utilize engineering approaches to reverse these molecular changes.
The goal is to translate these findings to first-in-human clinical trials. Learn more about recent publications from the lab.
Current Projects
- T Cell Engineering: We have leveraged evolutionary principles to design what we think are best-in-class T cell therapies for cancer. In a manuscript in press at Nature, we leveraged somatic mutations derived from T cell neoplasms in humans. These mutations confer fitness advantages that enable improved survival and fitness in the tumor microenvironment. When applied as potency enhancements to adoptive T cell therapies, we can cure solid tumors in syngeneic and xenograft models with small numbers of T cells.
- Curing Autoimmune Disease: We are using single-cell RNA-seq and other high dimensional assays to identify putative pathogenic T cells in autoimmune and autoinflammatory diseases. We are then utilizing CRISPR screens to identify putative targets for T cell reprogramming.
- T Cell Cancers: We have a robust and growing clinically and genomically annotated database of T cell lymphomas. We are leveraging this dataset to identify clinically actionable biomarkers and novel therapeutic targets.
We are looking for motivated, energetic postdoctoral fellows, graduate students, and bioinformaticians to join the Choi lab. If you are interested, please contact us:
Jaehyuk Choi
Northwestern University Feinberg School of Medicine
303 East Superior St.
Chicago, IL 60611
jaehyuk.choi@northwestern.edu.